Get the Stockscreener App
3.58
25.42%
-1.22
After Hours:
3.61
0.03
+0.84%
Anixa Biosciences Inc stock is traded at $3.58, with a volume of 2.15M.
It is down -25.42% in the last 24 hours and down -18.45% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$4.80
Open:
$5
24h Volume:
2.15M
Relative Volume:
8.25
Market Cap:
$117.84M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-9.1795
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
-25.26%
1M Performance:
-18.45%
6M Performance:
-0.56%
1Y Performance:
+22.18%
1-Day Range:
$3.52
$5.10
1-Week Range:
$3.52
$5.4566
52-Week Range:
$2.07
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.58 | 158.00M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine D - GuruFocus
Anixa Biosciences falls on phase 1 data for breast cancer vaccine - Seeking Alpha
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Anixa Biosciences Inc Announces Positive Phase 1 Data for Breast Cancer Vaccine - TradingView — Track All Markets
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial - marketscreener.com
Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cance - GuruFocus
Anixa’s breast cancer vaccine shows positive Phase 1 results - Investing.com
Anixa Biosciences (NASDAQ: ANIX) Phase 1 breast cancer vaccine data met endpoints with 74% immune response - Stock Titan
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - PR Newswire
Anixa Biosciences (NASDAQ: ANIX) sets Dec. 15 talk on Phase 1 breast cancer vaccine - Stock Titan
Anixa Biosciences (NASDAQ: ANIX) unveils final Phase 1 breast cancer vaccine results at 2025 SABCS - Stock Titan
Will Anixa Biosciences Inc. (CY71) stock beat Nasdaq index returns2025 Risk Factors & Real-Time Stock Entry Alerts - Newser
Why Anixa Biosciences Inc. (CY71) stock is trending on social mediaPortfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Will Anixa Biosciences Inc. stock see PE expansionWeekly Trading Summary & Risk Controlled Stock Pick Alerts - Newser
Is Anixa Biosciences Inc. stock undervalued vs historical averagesJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Who are in the management team of Anixa Biosciences, Inc.? - Markets Mojo
Is Anixa Biosciences Inc. stock a bargain at current levelsJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How risky is Anixa Biosciences Inc. (CY71) stock compared to peersLayoff News & Accurate Intraday Trading Signals - Newser
Can Anixa Biosciences Inc. (CY71) stock sustain double digit ROEJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
How Anixa Biosciences Inc. stock compares to growth peersJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
Anixa Biosciences (ANIX) Stock Analysis Report | Financials & Insights - Benzinga
Why retail investors pile into Anixa Biosciences Inc. stock2025 Institutional Moves & High Accuracy Trade Alerts - moha.gov.vn
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) - Aktiellt
Can Anixa Biosciences Inc. stock attract ESG capital inflows2025 Top Decliners & Low Risk High Win Rate Stock Picks - moha.gov.vn
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research - MarketBeat
Is Anixa Biosciences Inc. stock a top momentum playGold Moves & Precise Entry and Exit Recommendations - newser.com
How geopolitical risks impact Anixa Biosciences Inc. (CY71) stockWeekly Trade Recap & High Return Trade Guides - newser.com
Why Anixa Biosciences Inc. stock is recommended by analysts2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Anixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20 - MSN
Intraday pattern recognizer results for Anixa Biosciences Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Anixa Biosciences Inc. stock prediction for this week2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Can Anixa Biosciences Inc. (CY71) stock resist broad market declinesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Will Anixa Biosciences Inc. stock benefit from commodity pricesWeekly Trend Recap & Consistent Profit Alerts - newser.com
Backtesting results for Anixa Biosciences Inc. trading strategies2025 Key Lessons & Breakout Confirmation Alerts - newser.com
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):